Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

985671

registered interest
date	11/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to NHS England’s medicines optimisation CQUIN scheme, how NHS England calculates best value; and what the percentage importance is that NHS England applies in its scoring to the (a) cost, (b) efficacy and (c) safety of treatments when making that calculation.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	178258
answer	answer is ministerial correction date of answer 16/10/2018 answer text <p>Medicines Optimisation Commissioning for Quality and Innovation (CQUIN) requires trusts to adopt best value generic/biologic products in 90% of new patients within one quarter of guidance being made available and best value generic/biologic products in 80% of applicable existing patients within one year of guidance being made available (except if standard treatment course is less than six months). Further information is attached.</p><p>NHS England does not calculate best value. Best value is as defined within the commissioning framework and decisions about which product to use are made first on the basis of clinical judgement for individual patients and secondly on the basis of the overall value proposition offered by individual medicines. If more than one treatment is suitable, the best value biological medicine, including biosimilars, should be chosen taking into account transparently costed device training, any patient support programs offered by manufacturers, administration costs, dosage and price per dose.</p><p>The medicines are all licensed and therefore have been demonstrated to be safe and effective by the regulatory authorities.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/10/2018 16:35:25 answering member 4067 label Biography information for Steve Brine attachment 1 file name PQ178258 attachment.docx title Hospital Medicines Optimisation
tabling member	1533 label Biography information for Dame Diana Johnson

983301

registered interest
date	08/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 September 2018 to Question 170317, on Drugs, what estimate he has made of the number of weeks delay for medicines there will be at the UK border in the event that the UK leaves the EU without a deal; and whether that estimate has been revised since his letter of 23 August 2018 to the pharmaceutical industry.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	176238
answer	answer is ministerial correction date of answer 11/10/2018 answer text <p>Our request to suppliers is for them to store an additional six weeks’ stock. This will be on top of their business as usual contingency stockpiles. Six weeks is the current cross-Government planning assumption but will of course be subject to revision in light of future developments.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay question first answered 11/10/2018 15:58:35 answering member 4095 label Biography information for Steve Barclay
tabling member	3972 label Biography information for Baroness Chapman of Darlington

983302

registered interest
date	08/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 10 September 2018 to Question 170318 on Drugs, what the timeframe is for industry to start its stockpiling of medicines.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	176239
answer	answer is ministerial correction date of answer 11/10/2018 answer text <p>On 23 August 2018, the Department wrote to a number of pharmaceutical companies that supply the United Kingdom with medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the United Kingdom, over and above their business as usual operational buffer stocks, by 29 March 2019. Companies are best placed to decide on the timing for complying with the stockpiling request.</p><p> </p><p>Since writing to pharmaceutical companies, we have received good engagement from the industry who share our aims of ensuring patients maintain continuity of medicines supply. The Department continues to work closely with these companies to ensure that their UK stockpiles of medicines are sufficient to cope with any potential delays at the border that may arise in the short term from the unlikely event of a no-deal Brexit.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 176240 question first answered 11/10/2018 16:05:17 answering member 4095 label Biography information for Steve Barclay
tabling member	3972 label Biography information for Baroness Chapman of Darlington

983303

registered interest
date	08/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has the capability to monitor the stockpiling of medicines by industry after the UK leaves the EU, and what powers his Department has to compel suppliers to stockpile those medicines.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	176240
answer	answer is ministerial correction date of answer 11/10/2018 answer text <p>On 23 August 2018, the Department wrote to a number of pharmaceutical companies that supply the United Kingdom with medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks’ additional supply in the United Kingdom, over and above their business as usual operational buffer stocks, by 29 March 2019. Companies are best placed to decide on the timing for complying with the stockpiling request.</p><p> </p><p>Since writing to pharmaceutical companies, we have received good engagement from the industry who share our aims of ensuring patients maintain continuity of medicines supply. The Department continues to work closely with these companies to ensure that their UK stockpiles of medicines are sufficient to cope with any potential delays at the border that may arise in the short term from the unlikely event of a no-deal Brexit.</p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 176239 question first answered 11/10/2018 16:05:17 answering member 4095 label Biography information for Steve Barclay
tabling member	3972 label Biography information for Baroness Chapman of Darlington

983304

registered interest
date	08/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department's is taking to ensure the adequate supply of unlicensed medicines for use in clinical trials in the event that the UK leaves the EU without a deal.
tabling member constituency	Darlington
tabling member printed	Jenny Chapman
uin	176241
answer	answer is ministerial correction date of answer 11/10/2018 answer text <p>The Government has issued guidance on preparations to ensure continuity of supply of licensed medicines in the unlikely event of a no-deal. We recognise fully the importance of Investigational Medicinal Products supply and are planning communications to those organisations running clinical trials – life science industries trade associations and member companies, umbrella organisations for research charities and university hospitals, and more widely.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 11/10/2018 11:50:54 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	3972 label Biography information for Baroness Chapman of Darlington

983316

registered interest
date	08/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has (a) estimated the cost to medicines suppliers of stockpiling medicines for six weeks and (b) held discussions with the Chancellor of the Exchequer on using the public purse to meet that cost.
tabling member constituency	Sheffield Central
tabling member printed	Paul Blomfield
uin	176274
answer	answer is ministerial correction date of answer 11/10/2018 answer text <p>The Government is considering what support it may provide support to suppliers in respect to stockpiling medicines.</p><p> </p><p>The Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we’ve committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company or a specific medicine into the public domain.</p><p> </p><p>Prices for branded medicine products are fixed under the Pharmaceutical Price Regulation Scheme. For other generic medicines products there is a competitive market and prices increase and decrease on a regular basis as a result of market forces. We will continue to monitor prices and respond appropriately to ensure maximum value for money on behalf of the taxpayer is achieved.</p><p> </p><p>In the unlikely event of a no-deal the aim of the Department’s contingency planning is to ensure patients maintain the same access to medicines as they do at present.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 176275 176277 question first answered 11/10/2018 16:10:27 answering member 4095 label Biography information for Steve Barclay
tabling member	4058 label Biography information for Paul Blomfield

983317

registered interest
date	08/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what pharmaceutical (a) companies and (b) industry bodies his Department has held discussions with in relation to the potential use of the public purse to meet the costs of medicines stockpiling; and what costs the Government has proposed to cover.
tabling member constituency	Sheffield Central
tabling member printed	Paul Blomfield
uin	176275
answer	answer is ministerial correction date of answer 11/10/2018 answer text <p>The Government is considering what support it may provide support to suppliers in respect to stockpiling medicines.</p><p> </p><p>The Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we’ve committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company or a specific medicine into the public domain.</p><p> </p><p>Prices for branded medicine products are fixed under the Pharmaceutical Price Regulation Scheme. For other generic medicines products there is a competitive market and prices increase and decrease on a regular basis as a result of market forces. We will continue to monitor prices and respond appropriately to ensure maximum value for money on behalf of the taxpayer is achieved.</p><p> </p><p>In the unlikely event of a no-deal the aim of the Department’s contingency planning is to ensure patients maintain the same access to medicines as they do at present.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 176274 176277 question first answered 11/10/2018 16:10:27 answering member 4095 label Biography information for Steve Barclay
tabling member	4058 label Biography information for Paul Blomfield

983357

registered interest
date	08/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the effect of medicines stockpiling on (a) industry costs, (b) medicines pricing and (c) patient access to medicines.
tabling member constituency	Sheffield Central
tabling member printed	Paul Blomfield
uin	176277
answer	answer is ministerial correction date of answer 11/10/2018 answer text <p>The Government is considering what support it may provide support to suppliers in respect to stockpiling medicines.</p><p> </p><p>The Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we’ve committed to treating all information received confidentially, securely and to using it only for the purposes of the Department’s programme. That means not introducing information about a company or a specific medicine into the public domain.</p><p> </p><p>Prices for branded medicine products are fixed under the Pharmaceutical Price Regulation Scheme. For other generic medicines products there is a competitive market and prices increase and decrease on a regular basis as a result of market forces. We will continue to monitor prices and respond appropriately to ensure maximum value for money on behalf of the taxpayer is achieved.</p><p> </p><p>In the unlikely event of a no-deal the aim of the Department’s contingency planning is to ensure patients maintain the same access to medicines as they do at present.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency North East Cambridgeshire answering member printed Stephen Barclay grouped question UIN 176274 176275 question first answered 11/10/2018 16:10:27 answering member 4095 label Biography information for Steve Barclay
tabling member	4058 label Biography information for Paul Blomfield

979709

registered interest
date	01/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government how many technology appraisals NICE has undertaken for medicines which have successfully passed through the Early Access to Medicines Scheme; and how long it has taken for a NICE recommendation to be reached on each of those appraisals.
tabling member printed	Lord Carlile of Berriew
uin	HL10366
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>To date, the National Institute for Health and Care Excellence (NICE) has published final technology appraisal guidance on 18 drugs with a positive Scientific Opinion through the Early Access to Medicines Scheme. Information on the length of time between receipt of a positive Scientific Opinion and final NICE technology appraisal guidance for each drug is attached due to the size of the data.</p> answering member printed Lord O'Shaughnessy question first answered 15/10/2018 10:56:04 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name HL10366 table formatted.docx title Time between Scientific Opinion and NICE guidance
tabling member	1138 label Biography information for Lord Carlile of Berriew

980123

registered interest
date	01/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the implementation of the recommendations of the Independent Review of the Early Access to Medicines Scheme.
tabling member printed	Lord Carlile of Berriew
uin	HL10392
answer	answer is ministerial correction date of answer 15/10/2018 answer text <p>Since the publication of the independent review of the Early Access to Medicines Scheme (EAMS) the Government has made a number of improvements.</p><p>Partners have worked together to provide updated guidance on the benefits and entry requirements for EAMS and are developing further guidance on collecting real world data in the scheme to support National Institute for Health and Care Excellence appraisal.</p><p>Furthermore, the EAMS task group exists to provide a forum for industry to engage with Government, the devolved administrations and arm’s length bodies regarding EAMS, as per the recommendations of the 2016 review.</p> answering member printed Lord O'Shaughnessy question first answered 15/10/2018 13:52:46 answering member 4545 label Biography information for Lord O'Shaughnessy
tabling member	1138 label Biography information for Lord Carlile of Berriew